‘SMART’ Money Backs Catabasis $32.4M Series B
Lightstone Ventures led a $32.4 million Series B round for Catabasis Pharmaceuticals Inc., designed to complete a Phase II study of lead compound CAT-2003, currently under way in hypertriglyceridemia and in combination with statins in hypercholesterolemia.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter